Side-by-side · Research reference
BronchogenvsDSIP
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/35 cited
BHuman-MechanisticAUTO-DRAFTED8/36 cited
Bronchogen
Tetrapeptide Bioregulator · Khavinson-School
Research models: tissue culture / parenteral
DSIP
Sleep modulator · Anti-stress
SQ · Pre-sleep · Daily during cycle
01Mechanism of Action
Parameter
Bronchogen
DSIP
Primary target
Bronchial epithelial cellsKuzubova 2015
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
Pathway
Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
Downstream effect
Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015Titova 2017
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Feedback intact?
—
—
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
Antibody development
—
—
02Dosage Protocols
Parameter
Bronchogen
DSIP
Effective concentration (culture)
0.05 ng/mLZakutskiĭ 2006
Demonstrated in organotypic tissue culture of bronchial explants.
—
Treatment duration (animal)
1 month (30 days)Kuzubova 2015Titova 2017
Course duration in rat COPD models.
—
Evidence basis
Animal models (rat) / organotypic cultureTitova 2017Kuzubova 2015Zakutskiĭ 2006
No human clinical trials reported in available literature.
Human-mechanistic + early clinicalSchneider 1986
Tissue specificity
Selective for bronchopulmonary tissue
Part of Khavinson organ-specific bioregulator series.
—
Frequency
—
Once daily, pre-sleep
Lower / starter dose
—
50 mcg pre-sleep
Duration
—
8–12 weeks per cycle
Reconstitution
—
Bacteriostatic water
Timing
—
30–60 min pre-sleep
Half-life
—
Short plasma; CNS effects last hours
04Side Effects & Safety
Parameter
Bronchogen
DSIP
Animal safety profile
No adverse effects reported in published rat studies
Limited safety data; only animal models available.
—
Human data
Absent — no clinical trials in humans reported
—
Long-term effects
Unknown — maximum study duration 30 days in animals
—
Injection site reaction
—
Mild irritation
Drowsiness
—
Expected effect (intentional)
Vivid dreams
—
Anecdotally reported
Long-term safety
—
Limited modern RCT data
Pregnancy / OB
—
Avoid
Absolute Contraindications
Bronchogen
—DSIP
- ·Pregnancy / breastfeeding
- ·Concurrent CNS-depressant therapy without supervision
Relative Contraindications
Bronchogen
—DSIP
- ·Severe sleep apnoea (untreated)
- ·Concurrent benzodiazepine / opioid use
05Administration Protocol
Parameter
Bronchogen
DSIP
1. Research context only
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
Add 1–2 mL bacteriostatic water to vial.
2. Animal model protocol
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017Kuzubova 2015
SQ — abdomen. Rotate sites.
3. Organotypic culture
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006
30–60 min pre-sleep.
4. Khavinson bioregulator tradition
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Needle
—
29–31G insulin syringe.